Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Global Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61%
March 13, 2024 05:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, March 13, 2024 (GLOBE NEWSWIRE) -- The Global Psychedelic Drugs Market Size is to Grow from USD 2.9 Billion in 2023 to USD 8.7 Billion by 2033, at a Compound Annual Growth...
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief...
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
March 04, 2024 07:00 ET
|
Skye Bioscience, Inc.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and...
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
February 29, 2024 07:00 ET
|
Compass Pathways
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Highlights: COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line...
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
February 28, 2024 08:00 ET
|
Compass Therapeutics
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 07:05 ET
|
Apellis Pharmaceuticals, Inc.
Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than...
Molecular Diagnostics at Point of Care: Comprehensive Insights into the Rapid Market Growth and Advances from 2023-2027
February 22, 2024 11:58 ET
|
Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 -...
Healthcare Automation Market Size Projected to Reach USD 80.28 Bn by 2032
February 22, 2024 10:20 ET
|
Precedence Research
Ottawa, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The healthcare automation market size stood at USD 37.71 billion in 2024 and is expected to surpass around USD 56.39 billion by 2029, according to a study...
Spinal Rehab & Sports Medicine Announces Dr. Bob Meyer's 25-Year Anniversary in Sports Medicine
February 21, 2024 10:30 ET
|
Spinal Rehab Sports Medicine
AUSTIN, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spinal Rehab & Sports Medicine proudly announces Dr. Bob Meyer, D.C. unparalleled expertise in sports medicine, serving the vibrant community of...